Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance) Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Antineoplastic Combined Chemotherapy Protocols
  • Arteries
  • Prostatic Neoplasms
  • Prostatic Neoplasms, Castration-Resistant
  • Thromboembolism
  • Venous Thromboembolism

abstract

  • Bevacizumab was significantly associated with a greater risk of ATE in patients with metastatic, castration-resistant prostate cancer, but it was not significantly associated with the risk of VTE. Understanding clinical factors that increase the risk for experiencing ATE/VTE is essential to mitigate the risks and reduce the burden of these prevalent complications in cancer care.

publication date

  • April 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4368497

Digital Object Identifier (DOI)

  • 10.1002/cncr.29169

PubMed ID

  • 25417775

Additional Document Info

start page

  • 1025

end page

  • 31

volume

  • 121

number

  • 7